Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Deborah Schrag(Dana-Farber Brigham Cancer Center), M. Fruscione(Memorial Sloan Kettering Cancer Center), Joanne F. Chou(Memorial Sloan Kettering Cancer Center), Laura Sit(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Antonia V. Bennett(Memorial Sloan Kettering Cancer Center), Clifford A. Hudis(American Society of Clinical Oncology), Allison Barz Leahy(Memorial Sloan Kettering Cancer Center), Paul J. Novotny(Alliance for Clinical Trials in Oncology), Lauren J. Rogak(Memorial Sloan Kettering Cancer Center), Jeff A. Sloan(Mayo Clinic in Florida), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Dorothy Dulko(Memorial Sloan Kettering Cancer Center), Amylou C. Dueck(Mayo Clinic in Arizona), Paul Sabbatini(Memorial Sloan Kettering Cancer Center), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Thomas M. Atkinson(Memorial Sloan Kettering Cancer Center)
Cited by 2,644
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k